Stock comparison
Amicus Therapeutics
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
FOLD
Amicus Therapeutics
Market cap
$4.55B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | FOLD | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 42D | 79B | HALO |
| Benjamin Graham | 66D | 83A | HALO |
| Philip Fisher |
Side-by-side metrics
| Metric | FOLD | HALO |
|---|---|---|
| Market cap | $4.55B | $8.1B |
| P/E (TTM) | - | 24.0x |
| EV/EBIT | 139.7x | 10.2x |
| ROIC (TTM) | -6.46% | 23.65% |
| Gross margin | 87.91% | 81.24% |
| Net margin | -4.27% | 23.13% |
| Revenue CAGR 5y | 20.03% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
FOLD leads on
- P/E (TTM)-vs 24.0x+115%
- Gross margin87.91%vs 81.24%+8%
HALO leads on
- Net margin23.13%vs -4.27%+118%
More like HALO
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.